Review
. 2021 Jan; 13(2):.
doi: 10.3390/cancers13020287.

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Jim Middelburg 1 Kristel Kemper 2 Patrick Engelberts 2 Aran F Labrijn 2 Janine Schuurman 2 Thorbald van Hall 1 
Affiliations
  • PMID: 33466732
  •     199 References
  •     10 citations

Abstract

Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.

Keywords: CD3-bispecific antibody; T-cell co-stimulation; T-cell engager; antibody therapy; immuno-oncology; on-target off-tumor toxicity; solid tumors; tumor-associated antigens.

CD19 CAR T Cells.
Michel Sadelain.
Cell, 2017 Dec 16; 171(7). PMID: 29245005
Targeting cancer-derived adenosine: new therapeutic approaches.
Arabella Young, Deepak Mittal, John Stagg, Mark J Smyth.
Cancer Discov, 2014 Jul 19; 4(8). PMID: 25035124
Highly Cited. Review.
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.
Christiane R Stadler, Hayat Bähr-Mahmud, +4 authors, Ugur Sahin.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141353    Free PMC article.
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Yuexian Zhou, Huifang Zong, +9 authors, Jianwei Zhu.
J Exp Clin Cancer Res, 2020 May 14; 39(1). PMID: 32398042    Free PMC article.
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
Hiroshi Yano, Archana Thakur, +3 authors, Lawrence G Lum.
J Transl Med, 2014 Jul 11; 12. PMID: 25008236    Free PMC article.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J Turley, +39 authors, Thomas Powles.
Nature, 2018 Feb 15; 554(7693). PMID: 29443960    Free PMC article.
Highly Cited.
Human papillomavirus-associated cancers: A growing global problem.
Anshuma Bansal, Mini P Singh, Bhavana Rai.
Int J Appl Basic Med Res, 2016 Apr 30; 6(2). PMID: 27127735    Free PMC article.
Review.
Tissue-resident memory T cells at the center of immunity to solid tumors.
Derk Amsen, Klaas P J M van Gisbergen, Pleun Hombrink, Rene A W van Lier.
Nat Immunol, 2018 May 20; 19(6). PMID: 29777219
Highly Cited. Review.
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer.
Emma Eriksson, Jessica Wenthe, +2 authors, Gustav Ullenhag.
J Transl Med, 2016 Oct 01; 14(1). PMID: 27687804    Free PMC article.
Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity.
Ri Hong, Yuhai Zhou, +2 authors, Xiaoyun Wu.
Int Immunopharmacol, 2017 Nov 13; 54. PMID: 29128855
Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma.
Cédric Coulouarn, Bruno Clément.
J Hepatol, 2014 Feb 18; 60(6). PMID: 24530649
Review.
Suppression of T-cell responses by tumor metabolites.
Katrin Singer, Eva Gottfried, Marina Kreutz, Andreas Mackensen.
Cancer Immunol Immunother, 2011 Jan 18; 60(3). PMID: 21240484
Review.
COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
Anand Panchal, Pui Seto, +13 authors, Robert B DuBridge.
MAbs, 2020 Jul 21; 12(1). PMID: 32684124    Free PMC article.
Chemokines in cancer.
Melvyn T Chow, Andrew D Luster.
Cancer Immunol Res, 2014 Dec 07; 2(12). PMID: 25480554    Free PMC article.
Highly Cited. Review.
CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.
Kerstin Steinbrink, Edith Graulich, +2 authors, Alexander H Enk.
Blood, 2002 Mar 16; 99(7). PMID: 11895781
T Cell Dysfunction in Cancer.
Daniela S Thommen, Ton N Schumacher.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634943    Free PMC article.
Highly Cited. Review.
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Tao Dao, Dmitry Pankov, +14 authors, David A Scheinberg.
Nat Biotechnol, 2015 Sep 22; 33(10). PMID: 26389576    Free PMC article.
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.
John Scholler, Troy L Brady, +13 authors, Carl H June.
Sci Transl Med, 2012 May 04; 4(132). PMID: 22553251    Free PMC article.
Highly Cited.
Tissue instruction for migration and retention of TRM cells.
Norifumi Iijima, Akiko Iwasaki.
Trends Immunol, 2015 Aug 19; 36(9). PMID: 26282885    Free PMC article.
Review.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Hagop Kantarjian, Anthony Stein, +23 authors, Max S Topp.
N Engl J Med, 2017 Mar 02; 376(9). PMID: 28249141    Free PMC article.
Highly Cited.
Perspective: Designing T-Cell Engagers With Better Therapeutic Windows.
Omid Vafa, Nathan D Trinklein.
Front Oncol, 2020 May 01; 10. PMID: 32351885    Free PMC article.
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.
Erik Henke, Rajender Nandigama, Süleyman Ergün.
Front Mol Biosci, 2020 Mar 03; 6. PMID: 32118030    Free PMC article.
Review.
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.
M Compte, B Blanco, +5 authors, L Alvarez-Vallina.
Cancer Gene Ther, 2007 Jan 16; 14(4). PMID: 17218946
Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg.
Cell, 2011 Mar 08; 144(5). PMID: 21376230
Highly Cited. Review.
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
Colin E Correnti, George S Laszlo, +8 authors, Roland B Walter.
Leukemia, 2018 Mar 29; 32(5). PMID: 29588544    Free PMC article.
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Carlos Alberto Fajardo, Sonia Guedan, +5 authors, Ramon Alemany.
Cancer Res, 2017 Feb 02; 77(8). PMID: 28143835
Highly Cited.
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
Andrew G Jarnicki, Joanne Lysaght, Stephen Todryk, Kingston H G Mills.
J Immunol, 2006 Jul 05; 177(2). PMID: 16818744
Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.
B J Kroesen, A ter Haar, +7 authors, T H The.
Cancer Immunol Immunother, 1993 Nov 01; 37(6). PMID: 7902211
Therapeutic Antibodies against Intracellular Tumor Antigens.
Iva Trenevska, Demin Li, Alison H Banham.
Front Immunol, 2017 Sep 05; 8. PMID: 28868054    Free PMC article.
Review.
Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.
Dirk Zboralski, Kai Hoehlig, +2 authors, Axel Vater.
Cancer Immunol Res, 2017 Oct 01; 5(11). PMID: 28963140
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.
Liguo Niu, Simona Strahotin, +9 authors, Robert S Mittler.
J Immunol, 2007 Mar 21; 178(7). PMID: 17371976    Free PMC article.
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
R Riesenberg, A Buchner, H Pohla, H Lindhofer.
J Histochem Cytochem, 2001 Jun 19; 49(7). PMID: 11410615
A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Akira Iizuka, Chizu Nonomura, +9 authors, Yasuto Akiyama.
Clin Cancer Res, 2019 Feb 10; 25(9). PMID: 30737243
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig, James O Jones, +12 authors, Douglas T Fearon.
Proc Natl Acad Sci U S A, 2013 Nov 28; 110(50). PMID: 24277834    Free PMC article.
Highly Cited.
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.
Paulo C Rodriguez, Arnold H Zea, +5 authors, Augusto C Ochoa.
J Immunol, 2003 Jul 23; 171(3). PMID: 12874210
Highly Cited.
Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3.
Haruhiko Kamada, Shintaro Taki, +7 authors, Shin-ichi Tsunoda.
Biochem Biophys Res Commun, 2014 Dec 22; 456(4). PMID: 25528586
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Christianne Groeneveldt, Priscilla Kinderman, +7 authors, Nadine van Montfoort.
J Immunother Cancer, 2020 Oct 22; 8(2). PMID: 33082167    Free PMC article.
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Theodoros Giavridis, Sjoukje J C van der Stegen, +3 authors, Michel Sadelain.
Nat Med, 2018 May 29; 24(6). PMID: 29808005    Free PMC article.
Highly Cited.
On-target restoration of a split T cell-engaging antibody for precision immunotherapy.
Agnes Banaszek, Thomas G P Bumm, +18 authors, Gernot Stuhler.
Nat Commun, 2019 Nov 28; 10(1). PMID: 31772172    Free PMC article.
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.
M H Kraus, N C Popescu, S C Amsbaugh, C R King.
EMBO J, 1987 Mar 01; 6(3). PMID: 3034598    Free PMC article.
Highly Cited.
Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
Kota Iwahori, Sunitha Kakarla, +5 authors, Stephen Gottschalk.
Mol Ther, 2014 Aug 22; 23(1). PMID: 25142939    Free PMC article.
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
Sebastian Fm Häusler, Itsaso Montalbán Del Barrio, +5 authors, Jörg Wischhusen.
Am J Transl Res, 2014 Feb 04; 6(2). PMID: 24489992    Free PMC article.
Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Yasuhiko Ohshio, Koji Teramoto, +5 authors, Kazumasa Ogasawara.
Cancer Sci, 2014 Dec 09; 106(2). PMID: 25483888    Free PMC article.
ImmTACs for targeted cancer therapy: Why, what, how, and which.
Joanne Oates, Namir J Hassan, Bent K Jakobsen.
Mol Immunol, 2015 Feb 25; 67(2 Pt A). PMID: 25708206
Review.
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Silvia Martini, Mariangela Figini, +9 authors, Alessandro Satta.
Cells, 2020 Oct 08; 9(10). PMID: 33023194    Free PMC article.
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
Ende Zhao, Tomasz Maj, +22 authors, Weiping Zou.
Nat Immunol, 2015 Nov 03; 17(1). PMID: 26523864    Free PMC article.
Highly Cited.
Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation.
Leonid Gorelik, Stephanie Constant, Richard A Flavell.
J Exp Med, 2002 Jun 05; 195(11). PMID: 12045248    Free PMC article.
Highly Cited.
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.
Tao Dao, Sung Soo Mun, +11 authors, David A Scheinberg.
Oncoimmunology, 2019 May 31; 8(7). PMID: 31143508    Free PMC article.
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Steven R Leong, Siddharth Sukumaran, +20 authors, Andrew G Polson.
Blood, 2016 Dec 03; 129(5). PMID: 27908880    Free PMC article.
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Ralf Lutterbuese, Tobias Raum, +13 authors, Peter Kufer.
Proc Natl Acad Sci U S A, 2010 Jul 10; 107(28). PMID: 20616015    Free PMC article.
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Joshua D Freedman, Joachim Hagel, +9 authors, Leonard W Seymour.
EMBO Mol Med, 2017 Jun 22; 9(8). PMID: 28634161    Free PMC article.
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Timothy S Fisher, Andrea T Hooper, +13 authors, Chad May.
Cancer Immunol Immunother, 2017 Oct 27; 67(2). PMID: 29067496
FDA Approval: Blinatumomab.
Donna Przepiorka, Chia-Wen Ko, +15 authors, Richard Pazdur.
Clin Cancer Res, 2015 Sep 17; 21(18). PMID: 26374073
Highly Cited.
Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Xiuwen Guan, Jie Chen, +4 authors, Xuesi Chen.
Biomaterials, 2018 Apr 27; 171. PMID: 29698869
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Alexandra Sevko, Tillmann Michels, +6 authors, Viktor Umansky.
J Immunol, 2013 Jan 30; 190(5). PMID: 23359505    Free PMC article.
Cytokine release syndrome.
Alexander Shimabukuro-Vornhagen, Philipp Gödel, +6 authors, Michael S von Bergwelt-Baildon.
J Immunother Cancer, 2018 Jun 17; 6(1). PMID: 29907163    Free PMC article.
Highly Cited. Review.
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Eleanor M Scott, Egon J Jacobus, +10 authors, Margaret R Duffy.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31753017    Free PMC article.
Causes and consequences of tumour acidity and implications for treatment.
M Stubbs, P M McSheehy, J R Griffiths, C L Bashford.
Mol Med Today, 2000 Jan 19; 6(1). PMID: 10637570
Highly Cited. Review.
Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Rong Liu, Wenguo Jiang, +10 authors, Dongsheng Xiong.
J Immunother, 2010 May 14; 33(5). PMID: 20463597
Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS.
Sharad K Mittal, Kyung-Jin Cho, Satoshi Ishido, Paul A Roche.
J Biol Chem, 2015 Sep 27; 290(45). PMID: 26408197    Free PMC article.
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.
Mingpeng Fu, Qi He, +9 authors, Ping Lei.
Front Immunol, 2019 Jul 12; 10. PMID: 31293575    Free PMC article.
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
John Stagg, Upulie Divisekera, +5 authors, Mark J Smyth.
Proc Natl Acad Sci U S A, 2010 Jan 19; 107(4). PMID: 20080644    Free PMC article.
Highly Cited.
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Luke Russell, Kah Whye Peng, Stephen J Russell, Rosa Maria Diaz.
BioDrugs, 2019 Jul 20; 33(5). PMID: 31321623    Free PMC article.
Review.
Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies.
Tom J Harryvan, Els M E Verdegaal, +2 authors, Sjoerd H van der Burg.
J Clin Med, 2019 Nov 17; 8(11). PMID: 31731701    Free PMC article.
Review.
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Danielle Mandikian, Nene Takahashi, +13 authors, C Andrew Boswell.
Mol Cancer Ther, 2018 Jan 18; 17(4). PMID: 29339550
Highly Cited.
4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil.
Eri Yoshida, Daisuke Kudo, +6 authors, Kenichi Hakamada.
Anticancer Res, 2018 Oct 03; 38(10). PMID: 30275202
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
Shannon L Maude, David T Teachey, David L Porter, Stephan A Grupp.
Blood, 2015 May 23; 125(26). PMID: 25999455    Free PMC article.
Highly Cited. Review.
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Nathan D Trinklein, Duy Pham, +16 authors, Shelley Force Aldred.
MAbs, 2019 Jan 31; 11(4). PMID: 30698484    Free PMC article.
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.
Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, Johannes Vom Berg.
Front Oncol, 2018 Aug 10; 8. PMID: 30090763    Free PMC article.
Review.
Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Lei Huang, Kun Xie, +5 authors, Jianmin Fang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982167    Free PMC article.
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Caroline E Porter, Amanda Rosewell Shaw, +8 authors, Masataka Suzuki.
Mol Ther, 2020 Mar 08; 28(5). PMID: 32145203    Free PMC article.
Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts.
L Eikenes, M Tari, +2 authors, C de Lange Davies.
Br J Cancer, 2005 Jun 09; 93(1). PMID: 15942637    Free PMC article.
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
Barbara Molon, Stefano Ugel, +16 authors, Antonella Viola.
J Exp Med, 2011 Sep 21; 208(10). PMID: 21930770    Free PMC article.
Highly Cited.
Human Tumor Antigens and Cancer Immunotherapy.
Nathalie Vigneron.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161423    Free PMC article.
Review.
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Hong Xu, Ming Cheng, +3 authors, Nai-Kong V Cheung.
Cancer Immunol Res, 2014 Dec 30; 3(3). PMID: 25542634    Free PMC article.
Mechanisms regulating PD-L1 expression on tumor and immune cells.
Shuming Chen, George A Crabill, +5 authors, Suzanne L Topalian.
J Immunother Cancer, 2019 Nov 16; 7(1). PMID: 31730010    Free PMC article.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Mark R Middleton, Cheryl McAlpine, +16 authors, Mario Sznol.
Clin Cancer Res, 2020 Aug 21; 26(22). PMID: 32816891
Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.
S Huang, S Apasov, M Koshiba, M Sitkovsky.
Blood, 1997 Aug 15; 90(4). PMID: 9269779
Highly Cited.
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Eiji Suzuki, Veena Kapoor, +2 authors, Steven M Albelda.
Clin Cancer Res, 2005 Sep 17; 11(18). PMID: 16166452
Highly Cited.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Maxim Kebenko, Marie-Elisabeth Goebeler, +14 authors, Walter Fiedler.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221040    Free PMC article.
Retargeting of human regulatory T cells by single-chain bispecific antibodies.
Stefanie Koristka, Marc Cartellieri, +11 authors, Michael Bachmann.
J Immunol, 2011 Dec 21; 188(3). PMID: 22184723
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
P T Daniel, A Kroidl, +4 authors, A Pezzutto.
Blood, 1998 Dec 09; 92(12). PMID: 9845541
Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Juan Ma, Tengfei Shang, +4 authors, Man Zhang.
Invest New Drugs, 2019 Feb 02; 37(5). PMID: 30706335
Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Shasha Ruan, Ming Lin, +11 authors, Qiao Li.
Cancer Res, 2019 Dec 18; 80(4). PMID: 31843981    Free PMC article.
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division.
Geon Kook Lee, Hyeon Jin Park, +3 authors, Andrew L Mellor.
Immunology, 2002 Dec 04; 107(4). PMID: 12460190    Free PMC article.
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.
Marijn van der Neut Kolfschoten, Janine Schuurman, +11 authors, Paul W H I Parren.
Science, 2007 Sep 18; 317(5844). PMID: 17872445
Highly Cited.
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Karin Staflin, Christina L Zuch de Zafra, +21 authors, Teemu T Junttila.
JCI Insight, 2020 Apr 10; 5(7). PMID: 32271166    Free PMC article.
CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.
Yan Yan, Renfang Chen, +4 authors, Qinxue Hu.
Front Cell Dev Biol, 2019 Oct 22; 7. PMID: 31632965    Free PMC article.
Review.
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Antonio Marchini, Laurent Daeffler, +2 authors, Jean Rommelaere.
Front Immunol, 2019 Aug 24; 10. PMID: 31440242    Free PMC article.
Review.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Martina Geiger, Kay-Gunnar Stubenrauch, +18 authors, Christian Klein.
Nat Commun, 2020 Jun 26; 11(1). PMID: 32581215    Free PMC article.
Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Zhongping Yin, Ling Bai, +3 authors, Jiuwei Cui.
J Exp Clin Cancer Res, 2019 Sep 15; 38(1). PMID: 31519198    Free PMC article.
Review.
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Daniele V F Tauriello, Sergio Palomo-Ponce, +15 authors, Eduard Batlle.
Nature, 2018 Feb 15; 554(7693). PMID: 29443964
Highly Cited.
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
Danica Chiu, Richard Tavaré, +13 authors, Alison Crawford.
Cancer Immunol Res, 2020 Mar 19; 8(5). PMID: 32184296
Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.
Shashi Gujar, Jonathan G Pol, Guido Kroemer.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221036    Free PMC article.
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.
Jürgen Borlak, Florian Länger, +2 authors, Christian Dittrich.
Oncotarget, 2016 Apr 09; 7(19). PMID: 27058902    Free PMC article.
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
Jeong-Hwan Yoon, Su Myung Jung, +15 authors, Mizuko Mamura.
EMBO Mol Med, 2013 Oct 16; 5(11). PMID: 24127404    Free PMC article.
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
Edmund A Rossi, Diane L Rossi, +2 authors, David M Goldenberg.
Mol Cancer Ther, 2014 Jul 24; 13(10). PMID: 25053819
Bispecific antibodies in cancer immunotherapy.
Eva Dahlén, Niina Veitonmäki, Per Norlén.
Ther Adv Vaccines Immunother, 2018 Jul 13; 6(1). PMID: 29998217    Free PMC article.
Highly Cited. Review.
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Yaqi Zhao, Ibrahim Aldoss, +16 authors, Kathryn G Roberts.
Blood, 2020 Sep 04; 137(4). PMID: 32881995    Free PMC article.
Role of the immunosuppressive microenvironment in immunotherapy.
Garth W Tormoen, Marka R Crittenden, Michael J Gough.
Adv Radiat Oncol, 2018 Oct 30; 3(4). PMID: 30370351    Free PMC article.
Review.
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.
Diego Ellerman.
Methods, 2018 Nov 06; 154. PMID: 30395966
Review.
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Tobias Speck, Johannes P W Heidbuechel, +5 authors, Christine E Engeland.
Clin Cancer Res, 2018 Feb 14; 24(9). PMID: 29437789
Regulation of lymphocyte function by adenosine.
Joel Linden, Caglar Cekic.
Arterioscler Thromb Vasc Biol, 2012 Jul 10; 32(9). PMID: 22772752    Free PMC article.
Review.
CXCR3 in T cell function.
Joanna R Groom, Andrew D Luster.
Exp Cell Res, 2011 Mar 08; 317(5). PMID: 21376175    Free PMC article.
Highly Cited.
Redirected T Cell Cytotoxicity in Cancer Therapy.
Raphael A Clynes, John R Desjarlais.
Annu Rev Med, 2018 Nov 01; 70. PMID: 30379598
Review.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Geoffrey L Uy, Ibrahim Aldoss, +45 authors, John F DiPersio.
Blood, 2020 Sep 16; 137(6). PMID: 32929488    Free PMC article.
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy.
Miguel J Franquiz, Nicholas J Short.
Biologics, 2020 Feb 28; 14. PMID: 32103893    Free PMC article.
Review.
Frequent B7-H3 overexpression in craniopharyngioma.
Caili Chen, Yuelong Wang, +9 authors, Aiping Tong.
Biochem Biophys Res Commun, 2019 May 03; 514(2). PMID: 31043272
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.
Dionysos Slaga, Diego Ellerman, +15 authors, Teemu T Junttila.
Sci Transl Med, 2018 Oct 20; 10(463). PMID: 30333240
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
Joerg U Schmohl, Martin Felices, +2 authors, Daniel A Vallera.
Mol Ther, 2016 May 10; 24(7). PMID: 27157665    Free PMC article.
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
Jana de Sostoa, Carlos Alberto Fajardo, +3 authors, Ramon Alemany.
J Immunother Cancer, 2019 Jan 27; 7(1). PMID: 30683154    Free PMC article.
Highly Cited.
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
Alessandro Satta, Giulia Grazia, +8 authors, Mariangela Figini.
Front Immunol, 2019 Nov 12; 10. PMID: 31708930    Free PMC article.
Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Masanori Onda, Kazuto Kobayashi, Ira Pastan.
Proc Natl Acad Sci U S A, 2019 Feb 15; 116(10). PMID: 30760587    Free PMC article.
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.
Clare Y Slaney, Pin Wang, Phillip K Darcy, Michael H Kershaw.
Cancer Discov, 2018 Jul 18; 8(8). PMID: 30012854
Highly Cited. Review.
Collagen density regulates the activity of tumor-infiltrating T cells.
Dorota E Kuczek, Anne Mette H Larsen, +12 authors, Daniel H Madsen.
J Immunother Cancer, 2019 Mar 15; 7(1). PMID: 30867051    Free PMC article.
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
David T Teachey, Susan R Rheingold, +11 authors, Stephan A Grupp.
Blood, 2013 May 17; 121(26). PMID: 23678006    Free PMC article.
Highly Cited.
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Junpeng Qi, Xiuling Li, +5 authors, Christoph Rader.
Proc Natl Acad Sci U S A, 2018 May 31; 115(24). PMID: 29844189    Free PMC article.
Hybrid pH-sensitive nanogels surface-functionalized with collagenase for enhanced tumor penetration.
Xin Wang, Jie Luo, +4 authors, Rupei Tang.
J Colloid Interface Sci, 2018 May 02; 525. PMID: 29709781
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Z Wu, N V Cheung.
Pharmacol Ther, 2017 Aug 24; 182. PMID: 28834699    Free PMC article.
Review.
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.
Ping Wee, Zhixiang Wang.
Cancers (Basel), 2017 May 18; 9(5). PMID: 28513565    Free PMC article.
Highly Cited. Review.
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Marina Bacac, Tanja Fauti, +25 authors, Pablo Umaña.
Clin Cancer Res, 2016 Feb 11; 22(13). PMID: 26861458
Highly Cited.
Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.
Hong Qin, Beatrisa Lerman, +11 authors, Larry W Kwak.
Nat Med, 2014 May 27; 20(6). PMID: 24859530    Free PMC article.
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Ji Li, Robert Piskol, +9 authors, Teemu T Junttila.
Sci Transl Med, 2019 Sep 06; 11(508). PMID: 31484792
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
Michael A Morse, Amy C Hobeika, +4 authors, Timothy M Clay.
Blood, 2008 Jun 04; 112(3). PMID: 18519811    Free PMC article.
Highly Cited.
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Yuan Wen, Chun-Ting Wang, +7 authors, Yu-Quan Wei.
Cancer Sci, 2010 Sep 02; 101(11). PMID: 20804499
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
Michael Pishvaian, Michael A Morse, +7 authors, Crystal S Denlinger.
Clin Colorectal Cancer, 2016 Sep 07; 15(4). PMID: 27591895
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers.
Koen A Marijt, Elien M Doorduijn, Thorbald van Hall.
Mol Immunol, 2018 Apr 09; 113. PMID: 29627136
Review.
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Lillian Sun, Paul E Clavijo, +12 authors, Clint T Allen.
JCI Insight, 2019 Apr 05; 4(7). PMID: 30944253    Free PMC article.
Highly Cited.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Regina Jitschin, Domenica Saul, +7 authors, Dimitrios Mougiakakos.
J Immunother Cancer, 2018 Nov 07; 6(1). PMID: 30396365    Free PMC article.
Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats.
Ming-Peng Fu, Zi-Long Guo, +4 authors, Ping Lei.
Curr Med Sci, 2020 Mar 14; 40(1). PMID: 32166662
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Takuya Osada, Sandip P Patel, +3 authors, H Kim Lyerly.
Cancer Immunol Immunother, 2015 Mar 07; 64(6). PMID: 25742933
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Julie Vincent, Grégoire Mignot, +7 authors, François Ghiringhelli.
Cancer Res, 2010 Apr 15; 70(8). PMID: 20388795
Highly Cited.
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Giovanni Martinelli, Nicolas Boissel, +10 authors, Anthony Stein.
J Clin Oncol, 2017 Mar 30; 35(16). PMID: 28355115
Highly Cited.
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
Joshua D Freedman, Margaret R Duffy, +11 authors, Kerry D Fisher.
Cancer Res, 2018 Nov 20; 78(24). PMID: 30449733
Highly Cited.
Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.
Linlin Wang, Sayed Shahabuddin Hoseini, +2 authors, Nai-Kong Cheung.
Cancer Immunol Res, 2019 Oct 17; 7(12). PMID: 31615814    Free PMC article.
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.
Matthew Kraman, Paul J Bambrough, +6 authors, Douglas T Fearon.
Science, 2010 Nov 06; 330(6005). PMID: 21051638
Highly Cited.
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.
Ewelina Grywalska, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński.
Onco Targets Ther, 2018 Oct 17; 11. PMID: 30323625    Free PMC article.
Review.
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Steven L Highfill, Yongzhi Cui, +5 authors, Crystal L Mackall.
Sci Transl Med, 2014 May 23; 6(237). PMID: 24848257    Free PMC article.
Highly Cited.
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
Adam R Root, Wei Cao, +43 authors, Laird Bloom.
Antibodies (Basel), 2016 Mar 04; 5(1). PMID: 31557987    Free PMC article.
A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos.
Cancer Res, 2012 May 17; 72(10). PMID: 22589270    Free PMC article.
Highly Cited.
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Frans V Suurs, Marjolijn N Lub-de Hooge, Elisabeth G E de Vries, Derk Jan A de Groot.
Pharmacol Ther, 2019 Apr 28; 201. PMID: 31028837
Review.
Tregs activated by bispecific antibodies: Killers or suppressors?
Stefanie Koristka, Marc Cartellieri, +4 authors, Michael P Bachmann.
Oncoimmunology, 2015 May 08; 4(3). PMID: 25949920    Free PMC article.
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
Shintaro Taki, Haruhiko Kamada, +6 authors, Shin-ichi Tsunoda.
PLoS One, 2015 Dec 19; 10(12). PMID: 26678395    Free PMC article.
Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.
Kimberly M Lau, Ila M Saunders, Aaron M Goodman.
J Oncol Pharm Pract, 2020 Jul 02; 27(4). PMID: 32605497
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Rikke B Holmgaard, David A Schaer, +14 authors, Kyla E Driscoll.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866156    Free PMC article.
Highly Cited.
Mechanisms regulating T-cell infiltration and activity in solid tumors.
E Lanitis, D Dangaj, M Irving, G Coukos.
Ann Oncol, 2017 Oct 19; 28(suppl_12). PMID: 29045511
Highly Cited.
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.
Linda Borst, Sjoerd H van der Burg, Thorbald van Hall.
Clin Cancer Res, 2020 May 16; 26(21). PMID: 32409305
Review.
Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy.
Michael Alfred Ströhlein, Rolf Lefering, Dirk Rolf Bulian, Markus Maria Heiss.
Med Hypotheses, 2014 Jan 15; 82(3). PMID: 24411128
Replication-selective oncolytic viruses in the treatment of cancer.
Bart Everts, Henk G van der Poel.
Cancer Gene Ther, 2004 Oct 09; 12(2). PMID: 15472714
Review.
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Alison Crawford, Lauric Haber, +27 authors, Jessica R Kirshner.
Sci Transl Med, 2019 Jun 21; 11(497). PMID: 31217340
The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.
Cornelia Halin, M Lucila Scimone, +6 authors, Ulrich H von Andrian.
Blood, 2005 May 05; 106(4). PMID: 15870184    Free PMC article.
Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
Masaki Maruta, Toshiki Ochi, +6 authors, Masaki Yasukawa.
Sci Rep, 2019 Sep 19; 9(1). PMID: 31527633    Free PMC article.
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
Yariv Mazor, Kris F Sachsenmeier, +5 authors, William F Dall'Acqua.
Sci Rep, 2017 Jan 10; 7. PMID: 28067257    Free PMC article.
Proteases, extracellular matrix, and cancer: a workshop of the path B study section.
Yves A DeClerck, Arthur M Mercurio, +10 authors, Martin Padarathsingh.
Am J Pathol, 2004 Mar 25; 164(4). PMID: 15039201    Free PMC article.
Review.
TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Jingcheng Wu, Wenyi Zhao, +4 authors, Shuqing Chen.
Genomics Proteomics Bioinformatics, 2018 Sep 18; 16(4). PMID: 30223042    Free PMC article.
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
Juan Dubrot, Francisca Milheiro, +11 authors, Ignacio Melero.
Cancer Immunol Immunother, 2010 Mar 26; 59(8). PMID: 20336294
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.
Junpeng Qi, David Hymel, +2 authors, Christoph Rader.
Front Immunol, 2019 Sep 10; 10. PMID: 31497024    Free PMC article.
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Susanne M Steggerda, Mark K Bennett, +18 authors, Matthew I Gross.
J Immunother Cancer, 2017 Dec 20; 5(1). PMID: 29254508    Free PMC article.
Highly Cited.
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Dimitris Skokos, Janelle C Waite, +44 authors, George D Yancopoulos.
Sci Transl Med, 2020 Jan 10; 12(525). PMID: 31915305
Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
M E Ressing, J H de Jong, +6 authors, C J Melief.
Eur J Immunol, 1999 May 06; 29(4). PMID: 10229097
Elements of cancer immunity and the cancer-immune set point.
Daniel S Chen, Ira Mellman.
Nature, 2017 Jan 20; 541(7637). PMID: 28102259
Highly Cited. Review.
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells.
Belén Blanco, Phillip Holliger, Richard G Vile, Luis Alvarez-Vallina.
J Immunol, 2003 Jul 09; 171(2). PMID: 12847281
Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Wanru Ma, Juan Ma, +3 authors, Man Zhang.
Cancer Med, 2018 Sep 27; 7(10). PMID: 30253078    Free PMC article.
A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.
Jan Koster, Ronald H A Plasterk.
Sci Rep, 2019 May 01; 9(1). PMID: 31036835    Free PMC article.
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Markus M Heiss, Pawel Murawa, +17 authors, Simon L Parsons.
Int J Cancer, 2010 May 18; 127(9). PMID: 20473913    Free PMC article.
Highly Cited.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
WanJun Chen, Wenwen Jin, +5 authors, Sharon M Wahl.
J Exp Med, 2003 Dec 17; 198(12). PMID: 14676299    Free PMC article.
Highly Cited.
Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies.
Belén Blanco, Ángel Ramírez-Fernández, Luis Alvarez-Vallina.
Front Immunol, 2020 Sep 10; 11. PMID: 32903593    Free PMC article.
Review.
CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Androulla N Miliotou, Lefkothea C Papadopoulou.
Curr Pharm Biotechnol, 2018 Apr 19; 19(1). PMID: 29667553
Highly Cited. Review.
The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.
Huijun Zhao, Juan Ma, +2 authors, Man Zhang.
Invest New Drugs, 2018 Oct 31; 37(5). PMID: 30374653
Gene modification strategies for next-generation CAR T cells against solid cancers.
Yonggui Tian, Yilu Li, Yupei Shao, Yi Zhang.
J Hematol Oncol, 2020 May 20; 13(1). PMID: 32423475    Free PMC article.
Review.
Human T Cell Development, Localization, and Function throughout Life.
Brahma V Kumar, Thomas J Connors, Donna L Farber.
Immunity, 2018 Feb 22; 48(2). PMID: 29466753    Free PMC article.
Highly Cited. Review.
Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation.
Michael Hettich, Jayashree Lahoti, Shruthi Prasad, Gabriele Niedermann.
Cancer Res, 2016 Jun 16; 76(16). PMID: 27302161
Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.
Nina Deppisch, Peter Ruf, +4 authors, Ralph Mocikat.
Mol Cancer Ther, 2015 Jun 13; 14(8). PMID: 26063765
Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
Wanru Ma, Juan Ma, +2 authors, Man Zhang.
J Cancer, 2019 Oct 12; 10(21). PMID: 31602268    Free PMC article.
Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
Lei Zhao, Yudan Yang, +7 authors, Tao Zhang.
J Immunother, 2015 Jun 08; 38(6). PMID: 26049545
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Siler H Panowski, Tracy C Kuo, +27 authors, Barbra J Sasu.
Mol Cancer Ther, 2019 Aug 23; 18(11). PMID: 31434693
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Feng Yu, Xingbing Wang, +3 authors, Xiao-Tong Song.
Mol Ther, 2013 Oct 19; 22(1). PMID: 24135899    Free PMC article.
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
William R Strohl, Michael Naso.
Antibodies (Basel), 2019 Sep 24; 8(3). PMID: 31544847    Free PMC article.
Review.
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.
Jens Schreiner, Daniela S Thommen, +16 authors, Alfred Zippelius.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057429    Free PMC article.
High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager.
Nobuyuki Kurosawa, Yuka Wakata, +2 authors, Masaharu Isobe.
Sci Rep, 2019 Jul 10; 9(1). PMID: 31285464    Free PMC article.
Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Yoshika Iwata, Masanori Sasaki, +7 authors, Masayuki Mishima.
Toxicol Appl Pharmacol, 2019 Jul 22; 379. PMID: 31326447
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
A Rotte, J Y Jin, V Lemaire.
Ann Oncol, 2017 Oct 27; 29(1). PMID: 29069302
Highly Cited. Review.
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses.
Christianne Groeneveldt, Thorbald van Hall, +2 authors, Nadine van Montfoort.
Trends Immunol, 2020 Apr 01; 41(5). PMID: 32223932
Review.
L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells.
F Taheri, J B Ochoa, +5 authors, A C Ochoa.
Clin Cancer Res, 2001 Apr 13; 7(3 Suppl). PMID: 11300497
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Divya Mathur, Adam R Root, +24 authors, Puja Sapra.
Clin Cancer Res, 2020 Jan 31; 26(9). PMID: 31996389
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.
Marina Bacac, Christian Klein, Pablo Umana.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622073    Free PMC article.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
Stefani Spranger, Holly K Koblish, +3 authors, Thomas F Gajewski.
J Immunother Cancer, 2014 May 16; 2. PMID: 24829760    Free PMC article.
Highly Cited.
Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.
Aran F Labrijn, Joyce I Meesters, +8 authors, Paul W H I Parren.
Sci Rep, 2017 Jun 01; 7(1). PMID: 28559564    Free PMC article.
EpCAM and its potential role in tumor-initiating cells.
Sannia Imrich, Matthias Hachmeister, Olivier Gires.
Cell Adh Migr, 2012 Jun 01; 6(1). PMID: 22647938    Free PMC article.
Review.
MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
Hongjian Li, Cheng Huang, +11 authors, Aiping Tong.
Front Oncol, 2020 Sep 29; 10. PMID: 32984002    Free PMC article.
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Margherita Norelli, Barbara Camisa, +14 authors, Attilio Bondanza.
Nat Med, 2018 May 29; 24(6). PMID: 29808007
Highly Cited.
Bispecific antibodies: a mechanistic review of the pipeline.
Aran F Labrijn, Maarten L Janmaat, Janice M Reichert, Paul W H I Parren.
Nat Rev Drug Discov, 2019 Jun 09; 18(8). PMID: 31175342
Highly Cited. Review.
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Xianjie Jiang, Jie Wang, +12 authors, Zhaoyang Zeng.
Mol Cancer, 2019 Jan 17; 18(1). PMID: 30646912    Free PMC article.
Highly Cited. Review.
Manipulating IL-10 signalling blockade for better immunotherapy.
Guoying Ni, Tianfang Wang, +6 authors, Xiaosong Liu.
Cell Immunol, 2015 Jan 18; 293(2). PMID: 25596475
Review.
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.
Brian T Fife, Indira Guleria, +7 authors, Jeffrey A Bluestone.
J Exp Med, 2006 Nov 23; 203(12). PMID: 17116737    Free PMC article.
Highly Cited.
PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo.
Shunsuke Chikuma, Seigo Terawaki, +5 authors, Tasuku Honjo.
J Immunol, 2009 May 21; 182(11). PMID: 19454662
Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Alessandro Satta, Delia Mezzanzanica, +9 authors, Mariangela Figini.
MAbs, 2018 Jul 12; 10(7). PMID: 29993310    Free PMC article.
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics.
Xiaotian Zhong, Aaron M D'Antona.
Antibodies (Basel), 2021 Apr 04; 10(2). PMID: 33808165    Free PMC article.
Review.
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
Nadine Aschmoneit, Sophia Steinlein, +2 authors, Roland E Kontermann.
Sci Rep, 2021 Jul 08; 11(1). PMID: 34230555    Free PMC article.
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Karsten M Warwas, Marten Meyer, +9 authors, Frank Momburg.
Front Immunol, 2021 Sep 07; 12. PMID: 34484225    Free PMC article.
The state of the art of bispecific antibodies for treating human malignancies.
Shuhang Wang, Kun Chen, +16 authors, Ning Li.
EMBO Mol Med, 2021 Aug 26; 13(9). PMID: 34431224    Free PMC article.
Review.
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia.
Kinan Alhallak, Jennifer Sun, +9 authors, Abdel Kareem Azab.
Oncotarget, 2021 Sep 23; 12(19). PMID: 34548905    Free PMC article.
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
Roland E Kontermann, Guy Ungerechts, Dirk M Nettelbeck.
MAbs, 2021 Nov 09; 13(1). PMID: 34747345    Free PMC article.
Review.
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Nadine Aschmoneit, Lennart Kühl, Oliver Seifert, Roland E Kontermann.
J Immunother Cancer, 2021 Nov 17; 9(11). PMID: 34782429    Free PMC article.
Carboranes as unique pharmacophores in antitumor medicinal chemistry.
Yu Chen, Fukuan Du, +8 authors, Zhangang Xiao.
Mol Ther Oncolytics, 2022 Feb 11; 24. PMID: 35141397    Free PMC article.
Review.
A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
Yan Feng, Kun Xie, +8 authors, Jianmin Fang.
Life (Basel), 2022 Feb 26; 12(2). PMID: 35207448    Free PMC article.
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway.
Ye Shen, Jason S Eng, +5 authors, Olivier Nolan-Stevaux.
J Immunother Cancer, 2022 Mar 18; 10(3). PMID: 35296559    Free PMC article.